Erythropoietin therapy in renal failure.
It is indeed rare that a medication can do so much good and be associated with so few side effects and complications. The judicious use of Epo along with informed dosing practices will lead to an overwhelming favorable balance in the risk/benefit ratio of care. The move from a very specialized area of need into a more generic arena has done well for the development of drugs of this nature and may help stimulate further research in other "orphan" areas of drug need.
Paganini
E P
EP
Department of Hypertension/Nephrology, Cleveland Clinic Foundation, Ohio.
Miller
T
T
D000595:Amino Acid Sequence; D000818:Animals; D004921:Erythropoietin / Q000096:biosynthesis / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D008969:Molecular Sequence Data; D011994:Recombinant Proteins / Q000493:pharmacokinetics / Q000627:therapeutic use
D011994:Recombinant Proteins; D004921:Erythropoietin